S095033 in Combination With Paclitaxel as 2nd- or 3rd-line Treatment in Participants With Advanced or Metastatic ESCC

NCT05312372 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Strategic development reasons

Conditions

Esophageal Squamous Cell Carcinoma

Interventions

DRUG: Combination (S095033 + paclitaxel)

Sponsor

Institut de Recherches Internationales Servier

Collaborators

[object Object]